Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
Herold K, Gitelman S, Gottlieb P, Knetch L, Raymond R, and Ramos E
Diabetes Care. 2023 Oct 1;46(10):1848-1856
https://doi.org/10.2337/dc23-0675
Review : Incretins beyond type 2 diabetes
Mathieu Ch and Ahmadzai I
Diabetologia
https://doi.org/10.1007/s00125-023-05980-x
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Rosenstock J and Others
N Engl J Med 2023; 389:297-308
DOI: 10.1056/NEJMoa2303208
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frias J, Wu Q, Du Y et al
N Engl J Med. 2023 Jun 26.
www.doi.org/10.1056/NEJMoa2301972
Global Prevalence of Prediabetes
Rooney M, Fang M, Ogurstsova K, Ozkan B, Echouffo-Tcheugui E
Diabetes Care 2023;46(7):1388–1394
DOI: https://doi.org/10.2337/dc22-2376
Implementation of fully closed-loop insulin delivery for inpatients with diabetes: Real-world outcomes
Boughton C, Hartnell S, Hobday N, Lake A, Davenport K Et al
Diabet Med. 2023 Jun;40(6):e15092.
https://doi.org/10.1111/dme.15092
Comentarios recientes